NWNathan J. Wellington

Nathan J. Wellington

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nathan J. Wellington has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Temporal immune effects of Oral ketamine on PTSD: Transcriptomic evidence of short-term inflammation suppression and sustained immune Remodelling

    by Nathan J. Wellington, Bonnie L. Quigley, Ana P. Bouças, Megan Dutton, Adem T. Can, Jim Lagopoulos, Anna V. Kuballa

  • Open Access

    Methylome and transcriptome functional analysis identifies key biomarkers in ketamine’s sustained therapeutic effect on PTSD

    by Nathan J. Wellington, Ana P. Bouças, Paul E. Schwenn, Jim Lagopoulos, Bonnie L. Quigley, Anna V. Kuballa

    Background Ketamine has emerged as a rapid-acting therapeutic option for post-traumatic stress disorder (PTSD); however, its ability to sustain long-term therapeutic outcomes remains poorly understood. Identifying molecular biomarkers predictive of a sustained response to ketamine may enhance personalised treatment strategies. This study investigates the epigenetic and transcriptomic precursors underpinning ketamine’s long-term therapeutic efficacy in PTSD. Methods This study utilised data from the Oral Ketamine Trial of PTSD (OKTOP), an open-label, dose-ranging clinical study conducted between 2021 and 2024. Baseline differential DNA methylation and gene expression profiles of sustained responders (clinical response >1 month post-ketamine treatment) were compared against non-responders. Epigenomic and transcriptomic analyses were performed to identify differentially regulated genes associated with ketamine response. Results Baseline molecular analyses revealed significant differential methylation and transcriptomic profiles across 112 genes. Key biomarkers included DENND5B (cg02046589), ZFY (cg00272582), PDGFRA (cg21309167), CPT1A (cg10098373), AHRR (cg26076054), RPH3AL (cg17316718), CHI3L1 (cg19081101), UTY (cg04790916), LDHD (cg00004883), TBC1D16 (cg26287152), FAM66A (cg23285059), NME8 (cg02531859), EIF1AY (cg13308744), PCBP3 (cg13695288), PAQR6 (cg03954786), KCNK17 (cg19475903), PLPP2 (cg24452451), ANK1 (cg23668222), LINC00200 (C10ORF139, cg19282259), ALAS2 (cg07471703), ZBP1 (cg06305758), TACSTD2 (cg01821018), and PLEKHH3 (cg24455236). These biomarkers were implicated in pathways related to metabolism, transcriptional regulation, cell signalling, neuronal development, immune response, synaptic plasticity, and cytoskeletal organisation. Non-responders exhibited persistent dysregulation across these pathways, suggesting potential biological barriers to treatment efficacy. Clinically, sustained responders presented with higher baseline PTSD severity and demonstrated a response at lower ketamine doses compared to non-responders. Conclusions This study highlights the potential of methylomic and transcriptomic profiling to identify functional biomarkers predictive of ketamine response in PTSD. The observed molecular distinctions between responders and non-responders suggest a complex interplay between clinical presentation and treatment outcomes. These findings contribute to advancing precision medicine approaches for PTSD by informing biomarker-driven treatment stratification and optimisation of ketamine therapy.


  • Open Access

    Temporal Immune Effects of Oral Ketamine on PTSD: Transcriptomic Evidence of Short-Term Inflammation Suppression and Long-Term Immune Remodelling

    by Nathan J. Wellington, Bonnie L. Quigley, Ana P. Bouças, Megan Dutton, Adem T. Can, Jim Lagopoulos, Anna V. Kuballa

    Ketamine’s rapid acting symptom relief make it a promising intervention for PTSD. However, the mechanisms driving its long-term efficacy over weeks and months remain poorly understood. This study investigated the short-and long-term impacts on gene expression of a six-week subanesthetic oral ketamine trial in 23 PTSD participants (9 males, 14 females). Peripheral Blood Mononuclear Cells (PBMCs) were collected at baseline, one week (short-term), and four weeks (long-term) post oral ketamine for RNA sequencing and transcriptome analysis. Differential expression analysis identified substantial and persistent transcriptomic changes over time, with 533 genes upregulated and 621 downregulated across timepoints. Notably, there was a 37% increase in differential gene expression between the short-and long-term responses, accompanied by a 6.5-fold rise in expression magnitude and an 8.8-fold enhancement in pathway activity. Pathway analysis emphasised critical immune and inflammatory pathways that appear to be modulated by ketamine, including interferon alpha/beta signalling ( z = 4), IL-17 signalling pathway ( z = 3.36), and cytokine storm signalling ( z = 4.26), neutrophil degranulation (z = 6.0) and antimicrobial peptide signalling ( z = 1.63) which differed across timepoints. The findings suggest a transition from short-term inflammation suppression and antimicrobial activity to long-term sustained immune regulation, inflammation remodulation and tissue repair. Key cytokines, chemokines, interferons and antimicrobial peptides included, IL-6, IL-1β, IFI27, IL-10 signalling, CXCL8, SOCS1/3 and CAMP which represent central regulators of immune and inflammatory pathways. These molecular changes offer novel insights into the short-and long-term therapeutic potential of ketamine for PTSD and highlight avenues for precision psychiatry and individualised maintenance therapy to prevent relapse.

  • Open Access

    Molecular pathways of ketamine: A systematic review of immediate and sustained effects on PTSD

    by Nathan J. Wellington, Ana P. Boųcas, Jim Lagopoulos, Bonnie L. Quigley, Anna V. Kuballa

    Rationale: Existing studies predominantly focus on the molecular and neurobiological mechanisms underlying Ketamine’s acute treatment effects on post-traumatic stress disorder (PTSD). This emphasis has largely overlooked its sustained therapeutic effects, which hold significant potential for the development of targeted interventions. Objectives: This systematic review examines the pharmacokinetic and pharmacodynamic effects of ketamine on PTSD, differentiating between immediate and sustained molecular effects. Method: A comprehensive search across databases (Web of Science, Scopus, Global Health, PubMed) and grey literature yielded 317 articles, where 29 studies met the inclusion criteria. These studies included preclinical models and clinical trials, through neurotransmitter regulation, gene expression, synaptic plasticity, and neural pathways (PROSPERO ID: CRD42024582874). Results: We found accumulating evidence that the immediate effects of ketamine, which involve changes in GABA, glutamate, and glutamine levels, trigger the re-regulation of BDNF, enhancing synaptic plasticity via pathways such as TrkB and PSD-95. Other molecular influences also include c-Fos, GSK-3, HDAC, HCN1, and the modulation of hormones like CHR and ACTH, alongside immune responses (IL-6, IL-1β, TNF-α). Sustained effects arise from neurotransmitter remodulations and involve prolonged changes in gene expression. These include mTOR-mediated BDNF expression, alterations in GSK-3β, FkBP5, GFAP, ERK phosphorylation, and epigenetic modifications (DNMT3, MeCP2, H3K27me3, mir-132, mir-206, HDAC). Conclusion: These molecular changes promote long-term synaptic stability and re-regulation in key brain regions, contributing to prolonged therapeutic benefits. Understanding the sustained molecular and epigenetic mechanisms behind ketamine’s effects is critical for developing safe and effective personalised treatments, potentially leading to more effective recovery.


  • Open Access

    Clinical potential of epigenetic and microRNA biomarkers in PTSD

    by Nathan J. Wellington, Ana P. Boucas, Jim Lagopoulos, Anna V. Kuballa

    Molecular studies identifying alterations associated with PTSD have predominantly focused on candidate genes or conducted genome-wide analyses, often encountering issues with replicability. This review aims to identify robust bi-directional epigenetic and microRNA (miRNA) regulators focusing on their functional impacts on post-traumatic stress disorder (PTSD) and their utility in clinical diagnosis, whilst examining knowledge gaps in the existing research. A systematic search was conducted across multiple databases, including Web of Science, Scopus, Global Health (CABI), and PubMed, augmented by grey literature, yielding 3465 potential articles. Ultimately, 92 studies met the inclusion criteria and were analysed to pinpoint significant epigenetic changes with clinically relevant potential in PTSD. The selected studies explored histone modifications, CpG sites, single nucleotide polymorphisms (SNPs), and miRNA biomarkers. Specifically, nine studies examined epigenetic markers, detailing the influence of methylation on chromatin accessibility at histone positions H3K4, H3K9, and H3K36 within a PTSD context. Seventy-three studies investigated DNA methylation, identifying 20 hypermethylated and five hypomethylated CpG islands consistently observed in PTSD participants. Nineteen studies linked 88 SNPs to PTSD, with only one SNP replicated within these studies. Furthermore, sixteen studies focused on miRNAs, with findings indicating 194 downregulated and 24 upregulated miRNAs were associated with PTSD. Although there are epigenetic mechanisms that are significantly affected by PTSD, a granular deconstruction of these mechanisms elucidates the need to incorporate more nuanced approaches to identifying the factors that contribute to PTSD. Technological advances in diagnostic tools are driving the need to integrate detailed participant characteristics, trauma type, genetic susceptibilities, and best practices for robust reporting. This comprehensive approach will be crucial for enhancing the translational potential of PTSD research for clinical application.